“The new patent offers ground-breaking applications for formulators,” said B.G. Bairy, chairman and managing director of the Bayir Group. “We have been testing nanoparticle applications for a number of years, the impetus being the increasing demand from the consumer market for innovative applications of curcumin. The market has really pressed on the need for more bioavailable and readily soluble forms. The new nanoparticle formulation, along with the micronized product variants technology, allows for more diverse and ‘user-friendly’ applications, including food, beverage and OTC formulations.”
Bayir uses sophisticated extraction processes to obtain the purest and most concentrated forms of their organic ingredients, including curcumin. The company maintains nine manufacturing facilities worldwide with specialties including bacopa, glucosamine, chondroitin, organic extracts, and a wide range of botanicals such as garcinia cambogia.